CROSS-REACTIVITY OF ROCURONIUM WITH OTHER NEUROMUSCULAR BLOCKING-AGENTS

被引:0
|
作者
LAXENAIRE, MC
GASTIN, I
MONERETVAUTRIN, DA
WIDMER, S
GUEANT, JL
机构
[1] CHU HOP BRABOIS,PROT BIOCHEM LAB,NANCY,FRANCE
[2] CHU HOP CENT,DEPT MED & CLIN IMMUNOL,NANCY,FRANCE
关键词
IMMUNE RESPONSE; PRICK TEST; INTRADERMAL TEST; RAST ASSAY; RADIOIMMUNOASSAY; NEUROMUSCULAR RELAXANTS; ROCURONIUM; SUXAMETHONIUM; GALLAMINE; VECURONIUM; PANCURONIUM; ATRACURIUM;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The cross-reactivity of rocuronium with other neuromuscular blocking agents (NMBAs) was studied in 31 patients known to be allergic to a muscle relaxant. Tests for diagnosing cross-reactivity were skin tests (prick tests and intradermal tests: IDTs), detection by RAST assay of IgEs against the quaternary ammonium group (OAS-RIA: quaternary ammonium sepharose radio-immuno-assay), QAS-RIA inhibition test to detect IgE specificity, and leucocyte histamine release test (LHRT). Skin tests were performed with rocuronium, suxamethonium, gallamine, vecuronium, pancuronium, atracurium. The threshold for cross-reactivity was 10(-1) with all the NMBAs except for atracurium (10(-2)). The inhibition test and LHRT were performed with rocuronium and the NMBA responsible for the shock. Ten volunteers made up the control group for prick tests, OAS-RIA, LHRT. Crossreactivity was found in 30 patients out of 31. Rocuronium did not cross-react in 10 patients out of 31. They had negative cutaneous tests and negative LHRTs. In one of the five patients allergic to all the NMBAs available, rocuronium was the only one which did not cross-react. In those 10 patients, rocuronium may be safely used for subsequent anaesthesia. In terms of allergy, rocuronium appeared to be very close to the other steroidal NMBAs.
引用
收藏
页码:55 / 64
页数:10
相关论文
共 50 条
  • [41] Adenosine potentiation of neuromuscular blocking agents in guinea-pigs
    Nitahara, K
    Kornak, P
    Nagashima, H
    Vizi, ES
    Foldes, FF
    Dan, K
    BRITISH JOURNAL OF ANAESTHESIA, 2000, 84 (02) : 245 - 247
  • [42] Dosing of neuromuscular blocking agents in patients with obesity: A narrative review
    Erstad, Brian L.
    Barletta, Jeffrey F.
    ANAESTHESIA AND INTENSIVE CARE, 2021, 49 (02) : 98 - 104
  • [43] Selection of neuromuscular blocking agents in patients undergoing renal transplantation under general anesthesia
    Ma, HL
    Zhuang, XL
    CHINESE MEDICAL JOURNAL, 2002, 115 (11) : 1692 - 1696
  • [44] Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia
    Bulka, Catherine M.
    Terekhov, Maxim A.
    Martin, Barbara J.
    Dmochowski, Roger R.
    Hayes, Rachel M.
    Ehrenfeld, Jesse M.
    ANESTHESIOLOGY, 2016, 125 (04) : 647 - 655
  • [45] Neuromuscular Blocking Agents and Cancer: A Narrative Review
    Chen, Rui
    Sun, Yan
    Li, Yufan
    Dou, Xiaoke
    Dai, Maosha
    Sun, Shujun
    Lin, Yun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023, 2023
  • [46] Survey of how different groups of veterinarians manage the use of neuromuscular blocking agents in anesthetized dogs
    Martin-Flores, Manuel
    Sakai, Daniel M.
    Campoy, Luis
    Gleed, Robin D.
    VETERINARY ANAESTHESIA AND ANALGESIA, 2018, 45 (04) : 443 - 451
  • [47] Trends in the use of neuromuscular blocking agents, reversal agents and neuromuscular transmission monitoring: a single-centre retrospective cohort study
    Krijtenburg, Piet
    de Boer, Arjen
    Bash, Lori D.
    Scheffer, Gert Jan
    Keijzer, Christiaan
    Warle, Michiel C.
    PERIOPERATIVE MEDICINE, 2024, 13 (01)
  • [48] Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents
    Higashi, Michiko
    Tamura, Takahiro
    Adachi, Yushi U.
    JA CLINICAL REPORTS, 2019, 5 (1)
  • [49] Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs
    Loan, PB
    Connolly, FM
    Mirakhur, RK
    Kumar, N
    Farling, P
    BRITISH JOURNAL OF ANAESTHESIA, 1997, 78 (01) : 90 - 91
  • [50] Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
    Li, Liangxia
    Xu, Qianqian
    Liu, Yarui
    Pang, Liangfang
    Cui, Zhou
    Lu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15